Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: July 2007
-
By Kevin E. Noonan — The Federal Circuit decided the Integra Lifesciences I, Ltd. v. Merck KGaA case last week on remand from the Supreme Court, which had (in)famously overturned the CAFC last year. In its earlier decision, the Federal Circuit had affirmed the District Court’s finding that Merck’s activities did not fall…
-
By Robert Dailey — The United States Patent and Trademark Office (USPTO) and the Japan Patent Office (JPO) announced on Monday that the two offices had launched a free service that permits the offices to exchange patent application priority documents. A similar document exchange service already exists between the USPTO and the EPO…
-
By Kevin E. Noonan — The Federal Circuit addressed the contours of federal court declaratory judgment jurisdiction in light of the recent U.S. Supreme Court holding in MedImmune,Inc. v. Genentech, Inc. in a decision last week in Benitec Australia, Ltd. v. Nucleonics, Inc. Although the Federal Circuit’s application of the law was uneventful,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Sanofi-Aventis U S LLC et al. v. Sun Pharmaceutical Industries, Limited et al.2:07-cv-13107; filed July 24, 2007 in the Eastern District of…
-
By Donald Zuhn — On July 23, 2007, the Federal Circuit affirmed by a 2-1 vote a District Court judgment that U.S. Patent No. 5,081,154 (the ‘154 patent) was invalid for double patenting. The Federal Circuit also vacated the District Court’s holding that the ‘154 patent and U.S. Patent No. 5,001,161 (the ‘161…
-
September 18-19, 2007 – Pharma/Biotech Patent Boot Camp (American Conference Institute) – San Francisco, IL*** September 24-25, 2007 – Biosimilars 2007 (Scherago International, Inc.) – George Washington University, Washington, D.C. September 26-27, 2007 – Advanced Forum on Biotech Patents (American Conference Institute) – Boston, MA*** October 12, 2007 – Intellectual Property Law Summit 2007 (West…
-
Scherago International, Inc. has organized the Biosimilars 2007 conference to be held on September 24-25, 2007 at George Washington University in Washington, D.C. The conference is intended to "air the issues" and "raise the questions" regarding legislation under consideration in Congress that would provide the Food and Drug Administration (FDA) with the authority to regulate…
-
West LEGALWorks and the Intellectual Property Law Association of Chicago (IPLAC) are co-sponsoring the Intellectual Property Law Summit 2007 to be held on October 12, 2007 in Chicago, Illinois. Circuit Judge Richard Linn of the U.S. Court of Appeals for the Federal Circuit will be providing the keynote address, and Chief Judge James F. Holderman…
-
American Conference Institute (ACI) will be holding a forum on Biotech and Pharma Public-Private Partnerships on October 25-26, 2007 in Washington, D.C. The conference will provide a framework for overcoming issues that arise in bridging the innovation gap between industry and academia/government. In particular, ACI's faculty of experts from big pharma, small biotech, NIH and…
-
By Donald Zuhn — Ranbaxy Laboratories Ltd. announced today (July 26, 2007) that it had reached an agreement with GlaxoSmithKline in which GlaxoSmithKline would dismiss its patent infringement suit against Ranbaxy. GlaxoSmithKline had asserted its U.S. Patent No. 4,957,924, directed to Valacyclovir Hydrochloride, against Ranbaxy, which received final approval to market a generic…
Patent Docs 